Australia's Imagion Biosystems surges on US regulatory win for imaging agent
BUZZ-Australia's Imagion Biosystems surges on US regulatory win for imaging agent ** Shares of Imagion Biosystems IBX.AX rise as much as 52.9% to A$0.026, their highest since February 27
** Stock logs the largest intraday pct jump since early September 2025
** Medical imaging firm receives notice from the U.S. Food and Drug Administration for clearing the Investigational New Drug (IND) application for co's MagSense HER2 imaging agent
** MagSense technology is a class of MRI imaging agents that improves cancer detection
** Says FDA's allowance to proceed with the Phase 1b/2 clinical study in HER2+ breast cancer patients indicates that co comprehensively addressed all necessary logistical, analytical, quality and safety prerequisites
** More than 42.3 million shares change hands, 19.2 times the 30-day average
** Stock down 20% YTD, including the day's moves
(Reporting by Nikita Maria Jino in Bengaluru)
Recent news on Imagion Biosystems
See all newsBrief: Imagion Biosystems Secures AU$3.75M In Capital Raise Following FDA Clearance Of Phase 2 Clinical Trial
Brief: Imagion Biosystems Secures A$3.75 Million In Firm Commitments Under Capital Raising
Australia's Imagion Biosystems falls on discounted placement
Brief: Imagion Biosystems Seeks Trading Halt
Australia's Imagion Biosystems surges on US regulatory win for imaging agent